Kelly D. DeMarco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelly D. DeMarco has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Katherine C. Murphy
University of Massachusetts Chan Medical School 1 Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
28 shared publications - Marcus Ruscetti
University of Massachusetts Chan Medical School 1 Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
28 shared publications - Lihua Julie Zhu
Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA
27 shared publications - Jason R. Pitarresi
Division of Hematology–Oncology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, USA
26 shared publications - Lin Zhou
University of Massachusetts Chan Medical School 1 Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
26 shared publications - Hadiya K. Giwa
University of Massachusetts Chan Medical School 1 Department of Molecular, Cell, and Cancer Biology Worcester, Massachusetts
25 shared publications
Latest Publications
- 9 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF21
Senolytic Interventions Enhance the Antimetastatic Activity of Chemotherapy in Prostate Cancer
Cellular senescence is a common outcome of cytostatic and cytotoxic cancer therapies. Whereas in some contexts therapy-induced senescence can drive tumor growth suppression and antitumor immunity through the senescence-associated secretory phenotype (SASP), in others it can promote metastatic progression and immune suppression. A systematic interrogation of the impact of different classes of therapy on heterogeneous senescent phenotypes is required to effectively apply these drugs in specific cancer contexts and to rationally design combination treatments. Using genetically defined human and murine prostate cancer cell lines, we found that many classes of cancer therapeutics, including chemotherapies and targeted Aurora kinase and CDK inhibitors, could induce cellular senescence, with DNA-damaging agents mediating the most robust growth arrest and SASP. The SASP produced by chemotherapy-induced senescence, particularly with docetaxel, contained not only inflammatory factors that influence immune responses but also extracellular matrix remodeling factors that facilitate tumor cell dissemination. Though docetaxel treatment could induce senescence and reduce tumor growth in syngeneic prostate cancer mouse models, it was not sufficient to activate antitumor immunity or slow metastatic dissemination. Senolytic therapies targeting the prosurvival BCL2 and IAP pathways upregulated after docetaxel-induced senescence effectively killed senescent tumor cells through multiple cell death pathways, remodeling the inflammatory SASP to repolarize myeloid phenotypes and potentiate CD8+ T-cell activation to further block tumor growth and suppress metastasis. These results suggest that senolytic agents can enhance the immunogenicity and antimetastatic potential of chemotherapy used for treating patients with advanced prostate cancer. Significance: Combining senescence-inducing chemotherapy with senolytic agents can both eliminate senescent cells and enhance the inflammatory output of senescence to drive T-cell immunity and metastasis suppression in prostate cancer.
- 9 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF21
Senolytic Interventions Enhance the Antimetastatic Activity of Chemotherapy in Prostate Cancer
Cellular senescence is a common outcome of cytostatic and cytotoxic cancer therapies. Whereas in some contexts therapy-induced senescence can drive tumor growth suppression and antitumor immunity through the senescence-associated secretory phenotype (SASP), in others it can promote metastatic progression and immune suppression. A systematic interrogation of the impact of different classes of therapy on heterogeneous senescent phenotypes is required to effectively apply these drugs in specific cancer contexts and to rationally design combination treatments. Using genetically defined human and murine prostate cancer cell lines, we found that many classes of cancer therapeutics, including chemotherapies and targeted Aurora kinase and CDK inhibitors, could induce cellular senescence, with DNA-damaging agents mediating the most robust growth arrest and SASP. The SASP produced by chemotherapy-induced senescence, particularly with docetaxel, contained not only inflammatory factors that influence immune responses but also extracellular matrix remodeling factors that facilitate tumor cell dissemination. Though docetaxel treatment could induce senescence and reduce tumor growth in syngeneic prostate cancer mouse models, it was not sufficient to activate antitumor immunity or slow metastatic dissemination. Senolytic therapies targeting the prosurvival BCL2 and IAP pathways upregulated after docetaxel-induced senescence effectively killed senescent tumor cells through multiple cell death pathways, remodeling the inflammatory SASP to repolarize myeloid phenotypes and potentiate CD8+ T-cell activation to further block tumor growth and suppress metastasis. These results suggest that senolytic agents can enhance the immunogenicity and antimetastatic potential of chemotherapy used for treating patients with advanced prostate cancer. Significance: Combining senescence-inducing chemotherapy with senolytic agents can both eliminate senescent cells and enhance the inflammatory output of senescence to drive T-cell immunity and metastasis suppression in prostate cancer.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 5 shows that tumor cell-specific p16 or p21 knockout enhances DC and CD8+ T cell accumulation but has no effect on the SASP or T cell activity in transplanted prostate tumors.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 5 shows that tumor cell-specific p16 or p21 knockout enhances DC and CD8+ T cell accumulation but has no effect on the SASP or T cell activity in transplanted prostate tumors.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Cellular senescence is a well-established tumor-suppressive cell-cycle arrest program. However, chronic inflammation through the senescence-associated secretory phenotype (SASP) can alternatively drive immune suppression and cancer progression. Using prostate cancer patient samples and murine models, we find p16+ and p21+ senescent cells accumulate throughout malignant progression and associate with immune suppression. Single-cell sequencing revealed that p16 and p21 mark distinct epithelial and stromal senescent populations, with p21+ nontumor cells expressing the highest SASP. p21+ stromal cell removal blocked the SASP to reverse immune suppression and slow tumor growth. Senolytic BCL-xL inhibitor treatment could clear p21+ stromal senescent cells, reactivating antitumor CD8+ T-cell immunity and inhibiting prostate tumor progression in mice. Suppression of BCL-xL or p21 also potentiated anti–PD-1 immune checkpoint blockade (ICB) in preclinical prostate cancer models. Our findings demonstrate that targeting p21+ senescent stromal populations can yield therapeutic benefits in advanced prostate cancer through activating antitumor immunity and enhancing immunotherapy outcomes.Significance:Senescent cells accumulate in the tumor and stroma throughout prostate cancer progression and are associated with immune suppression in patients and mice. Senolytic strategies to clear p21+ senescent stromal cells can prevent prostate cancer progression and reactive cytotoxic T-cell immunity to potentiate anti–PD-1 ICB in advanced disease.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Cellular senescence is a well-established tumor-suppressive cell-cycle arrest program. However, chronic inflammation through the senescence-associated secretory phenotype (SASP) can alternatively drive immune suppression and cancer progression. Using prostate cancer patient samples and murine models, we find p16+ and p21+ senescent cells accumulate throughout malignant progression and associate with immune suppression. Single-cell sequencing revealed that p16 and p21 mark distinct epithelial and stromal senescent populations, with p21+ nontumor cells expressing the highest SASP. p21+ stromal cell removal blocked the SASP to reverse immune suppression and slow tumor growth. Senolytic BCL-xL inhibitor treatment could clear p21+ stromal senescent cells, reactivating antitumor CD8+ T-cell immunity and inhibiting prostate tumor progression in mice. Suppression of BCL-xL or p21 also potentiated anti–PD-1 immune checkpoint blockade (ICB) in preclinical prostate cancer models. Our findings demonstrate that targeting p21+ senescent stromal populations can yield therapeutic benefits in advanced prostate cancer through activating antitumor immunity and enhancing immunotherapy outcomes.Significance:Senescent cells accumulate in the tumor and stroma throughout prostate cancer progression and are associated with immune suppression in patients and mice. Senolytic strategies to clear p21+ senescent stromal cells can prevent prostate cancer progression and reactive cytotoxic T-cell immunity to potentiate anti–PD-1 ICB in advanced disease.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 6 shows that p16 ablation in the stroma has no impact on prostate tumor or immune responses.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 6 shows that p16 ablation in the stroma has no impact on prostate tumor or immune responses.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 8 shows that ABT-263 and anti-PD-1 combination therapy reduces senescent cell accumulation, fibrosis, and myeloid cell recruitment in advanced prostate cancer, culminating in enhanced animal survival.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 8 shows that ABT-263 and anti-PD-1 combination therapy reduces senescent cell accumulation, fibrosis, and myeloid cell recruitment in advanced prostate cancer, culminating in enhanced animal survival.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 7 shows that ABT-263 preferentially targets p21+ stromal cells, leading to reduced pro-myeloid SASP expression and immature myeloid cells and enhanced cytotoxic lymphocyte immunity.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 7 shows that ABT-263 preferentially targets p21+ stromal cells, leading to reduced pro-myeloid SASP expression and immature myeloid cells and enhanced cytotoxic lymphocyte immunity.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 4 shows that GCV-mediated ablation of p16+ senescent epithelial cells fails to repress the SASP or fully activate NK and CD8+ T cells in CP-3MR prostates.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 4 shows that GCV-mediated ablation of p16+ senescent epithelial cells fails to repress the SASP or fully activate NK and CD8+ T cells in CP-3MR prostates.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 and Table S2 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Table S1 shows sgRNA sequences. Supplementary Table S2 shows RT-qPCR primer sequences.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 and Table S2 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Table S1 shows sgRNA sequences. Supplementary Table S2 shows RT-qPCR primer sequences.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 2 shows that p16 and p21 expression in human prostate cancers correlates with poor CD8+ T cell infiltration.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 2 shows that p16 and p21 expression in human prostate cancers correlates with poor CD8+ T cell infiltration.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 3 shows that p21+ cells have a different stromal localization and SASP profile compared to p16+ cells in CP mouse prostate tumors.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy
Supplementary Figure 3 shows that p21+ cells have a different stromal localization and SASP profile compared to p16+ cells in CP mouse prostate tumors.